R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Increasing Chimerism after Allogeneic Stem Cell Transplantation Is Associated with Longer Survival Time
X. Tang,Gheath Alatrash,Jing Ning,Haroon Jakher,Patricia D. Stafford,Madhushree Zope,Elizabeth J. Shpall,Roy B. Jones,Richard E. Champlin,Peter F. Thall,Borje S. Andersson +10 more
TL;DR: Analysis of data from 195 patients with acute myelogenous leukemia or myelodysplastic syndrome who achieved complete remission after allo-SCT showed that a binary indicator of complete (100%) donor chimerism and increasing percent of donor T cells were significantly associated with longer OS, whereas decreasing percent of donors T-cells was highly significant associated with shorter OS.
Journal ArticleDOI
Low-dose alemtuzumab (Campath ® ) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics
Issa F. Khouri,Maher Albitar,Rima M. Saliba,Cindy Ippoliti,Y. C. Ma,Michael J. Keating,Richard E. Champlin +6 more
TL;DR: Alemtuzumab is effective in reducing the risk of acute graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (ASCT) and may also delay immune reconstitution and reduce graft-Versus-leukemia effects.
Journal ArticleDOI
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation.
Amanda Olson,Ruitao Lin,David Marin,Hind Rafei,Mustafa Bdaiwi,Peter F. Thall,Rafet Basar,Ala Abudayyeh,Pinaki P. Banerjee,Fleur M. Aung,Indresh Kaur,Glorette Abueg,Sheetal S Rao,Roy F. Chemaly,Victor E. Mulanovich,Gheath Alatrash,Amin M. Alousi,Borje S. Andersson,Paolo Anderlini,Qaiser Bashir,Karla M Castro,May Daher,Isabel M Galvan,Chitra Hosing,Jin S. Im,Roy B. Jones,Partow Kebriaei,Issa F. Khouri,Rohtesh S. Mehta,Jeffrey J. Molldrem,Yago Nieto,Betul Oran,Uday R. Popat,Muzaffar H. Qazilbash,Gabriela Rondon,Neeraj Saini,Bryan P Spencer,Samer A. Srour,Dominique Washington,Melissa Barnett,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +42 more
TL;DR: BK virus-associated hemorrhagic cystitis (BKV-HC) is a common complication of allogenic hematopoietic stem cell transplantation (AHSCT), particularly in recipients of alternative donor trans....
Journal ArticleDOI
The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes
Nancy H. Collins,Adrian P. Gee,April G. Durett,Fangyu Kan,Mei-Jie Zhang,Richard E. Champlin,Dennis L. Confer,Mary Eapen,Alan Howard,Roberta King,Mary J. Laughlin,Robert J. Plante,Michelle Setterholm,Stephen R. Spellman,Carolyn A. Keever-Taylor,John E. Wagner,Daniel J. Weisdorf +16 more
TL;DR: To test the hypothesis that the outcome of hematopoietic stem cell (HSC) grafts is at least partially determined by the cellular composition of the graft, the National Marrow Donor Program analyzed the correlation of cellular phenotypes of unrelated grafts with graft outcome.
Journal ArticleDOI
Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Joseph Sassine,Joseph Sassine,Fareed Khawaja,Terri Lynn Shigle,Victoria Wehr Handy,Farnaz Foolad,Samuel L. Aitken,Ying Jiang,Richard E. Champlin,Elizabeth J. Shpall,Katy Rezvani,Ella J. Ariza-Heredia,Roy F. Chemaly +12 more
TL;DR: In this article, the effect of primary letermovir prophylaxis in this population on the incidence and outcomes of refractory or resistant CMV infections was explored, and the results showed that letermolimovir with letermovalve agent was associated with a reduction in clinically significant CMV infection in clinical trials of CMV-seropositive HCT recipients.